Expert Panel Approves Roche’s Orphan Drug For Blood Disorder, Waives Local Clinical Trials

The subject expert committee (SEC) has asked Roche to conduct a phase 4 study in India and, accordingly, the company should submit a protocol for the study within three months of the grant of permission